Brief: FDA Approves Targeted Treatment For Rare Duchenne Muscular Dystrophy Mutation
12/08/2020 19:22
Aug 12 (Reuters) - U.S. FDA:
* FDA APPROVES TARGETED TREATMENT FOR RARE DUCHENNE MUSCULAR
DYSTROPHY MUTATION
* FDA SAYS GRANTING ACCELERATED APPROVAL TO NS PHARMA'S
VILTEPSO
INJECTION FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Source text for Eikon: ID:nPn57hfq5a
Further company coverage: 4516.T
((reuters.briefs@thomsonreuters.com;))
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)